Corcept Therapeutics Stock Price, News & Analysis (NASDAQ:CORT) $26.78 -0.26 (-0.96%) (As of 11:50 AM ET) Add Compare Share Share Today's Range$26.50▼$27.1050-Day Range$24.82▼$32.9952-Week Range$17.86▼$34.28Volume101,742 shsAverage Volume717,984 shsMarket Capitalization$2.76 billionP/E Ratio33.06Dividend YieldN/APrice Target$32.19 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Corcept Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside19.0% Upside$32.19 Price TargetShort InterestBearish17.39% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.03Based on 18 Articles This WeekInsider TradingSelling Shares$2.87 M Sold Last QuarterProj. Earnings Growth-10.99%From $0.91 to $0.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector551st out of 957 stocksPharmaceutical Preparations Industry223rd out of 397 stocks 2.3 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.19, Corcept Therapeutics has a forecasted upside of 19.0% from its current price of $27.04.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.39% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 68.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.59. Previous Next 2.2 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Corcept Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows5 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,868,415.00 in company stock.Percentage Held by Insiders18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.80% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to decrease by -10.99% in the coming year, from $0.91 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 33.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 33.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.83.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 5.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corcept Therapeutics Stock (NASDAQ:CORT)Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comInsider Sell: Joseph Lyon of Corcept Therapeutics Inc (CORT) Sells 5,000 SharesDecember 4, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) to Post Q3 2024 Earnings of $0.19 Per Share, Zacks Research ForecastsDecember 7, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." December 2, 2023 | benzinga.comCorcept Therapeutics Stock (NASDAQ:CORT) Dividends: History, Yield and DatesDecember 2, 2023 | americanbankingnews.comZacks Research Analysts Raise Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)December 1, 2023 | finance.yahoo.comWhy Is Corcept (CORT) Up 0.7% Since Last Earnings Report?November 15, 2023 | morningstar.comCorcept Therapeutics Inc CORTNovember 14, 2023 | finance.yahoo.comShould Weakness in Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?December 7, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 13, 2023 | seekingalpha.comAnalyzing Corcept's Strategic Shift In A Competitive Pharma LandscapeNovember 10, 2023 | stocknews.comVertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?November 7, 2023 | msn.comTruist Securities Upgrades Corcept Therapeutics (CORT)November 6, 2023 | msn.comTruist upgrades Corcept to buy, cites market potential for relacorilantNovember 6, 2023 | markets.businessinsider.comWhere Corcept Therapeutics Stands With AnalystsNovember 4, 2023 | finance.yahoo.comInsider Sell: Chief Accounting Officer Joseph Lyon Sells 5,000 Shares of Corcept Therapeutics IncNovember 2, 2023 | finance.yahoo.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comCorcept (CORT) Beats on Q3 Earnings, Raises '23 Sales ViewNovember 1, 2023 | finance.yahoo.comCorcept Therapeutics Inc (CORT) Reports 22% Revenue Increase in Q3 2023November 1, 2023 | finance.yahoo.comCorcept Appoints Monica Tellado as President, Emerging MarketsOctober 31, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Corcept Therapeutics (CORT)October 26, 2023 | finance.yahoo.comCorcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 12, 2023 | finance.yahoo.comTempest (TPST) Up as First-Line Liver Cancer Study Meets GoalsOctober 5, 2023 | finance.yahoo.comPulling back 20% this week, Corcept Therapeutics' NASDAQ:CORT) five-year decline in earnings may be coming into investors focusOctober 4, 2023 | finance.yahoo.comKezar (KZR) Falls 10% on Strategic Update, Reduces WorkforceOctober 3, 2023 | msn.comTruist Securities Reiterates Corcept Therapeutics (CORT) Hold RecommendationOctober 2, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Corcept TherapeuticsSeptember 30, 2023 | msn.comCorcept Therapeutics plunges amid patent trial with Teva (update)See More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees299Year Founded1998Price Target and Rating Average Stock Price Target$32.19 High Stock Price Target$47.50 Low Stock Price Target$22.00 Potential Upside/Downside+19.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.81 Trailing P/E Ratio33.38 Forward P/E Ratio29.71 P/E GrowthN/ANet Income$101.42 million Net Margins20.20% Pretax Margin24.89% Return on Equity18.99% Return on Assets15.67% Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.48 Sales & Book Value Annual Sales$401.86 million Price / Sales6.94 Cash Flow$1.01 per share Price / Cash Flow26.82 Book Value$4.66 per share Price / Book5.80Miscellaneous Outstanding Shares103,080,000Free Float83,908,000Market Cap$2.79 billion OptionableOptionable Beta0.35 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 66)Co-Founder, President, CEO & Director Comp: $1.82MMr. Atabak Mokari (Age 46)CFO & Treasurer Comp: $760.75kDr. Hazel Hunt Ph.D. (Age 63)Chief Scientific Officer Comp: $895.16kMr. Sean Maduck (Age 46)President of Corcept Endocrinology Comp: $823.42kMr. Gary Charles Robb (Age 60)Chief Business Officer & Secretary Comp: $963kMr. Joseph Douglas Lyon (Age 44)Chief Accounting Officer Ms. Amy FloodChief Human Resources & Communications OfficerDr. William Guyer Pharm.D. (Age 55)Chief Development Officer Ms. Monica Tellado (Age 50)President of Emerging Markets More ExecutivesKey CompetitorsRa PharmaceuticalsNASDAQ:RARXSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXPerrigoNYSE:PRGOBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 20,400 shares on 12/6/2023Ownership: 0.000%Gary Charles RobbSold 1,381 sharesTotal: $36,278.87 ($26.27/share)Joseph Douglas LyonSold 2,432 sharesTotal: $63,232.00 ($26.00/share)Sean MaduckSold 25,000 sharesTotal: $639,000.00 ($25.56/share)Joseph Douglas LyonSold 2,568 sharesTotal: $66,768.00 ($26.00/share)View All Insider TransactionsView All Institutional Transactions CORT Stock Analysis - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CORT shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price target for 2024? 7 brokers have issued 12 month price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $22.00 to $47.50. On average, they anticipate the company's share price to reach $32.19 in the next twelve months. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2023? Corcept Therapeutics' stock was trading at $20.31 at the beginning of the year. Since then, CORT stock has increased by 33.1% and is now trading at $27.04. View the best growth stocks for 2023 here. Are investors shorting Corcept Therapeutics? Corcept Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 15,270,000 shares, an increase of 8.1% from the October 31st total of 14,120,000 shares. Based on an average daily volume of 739,700 shares, the days-to-cover ratio is presently 20.6 days. Approximately 17.4% of the company's shares are short sold. View Corcept Therapeutics' Short Interest. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The biotechnology company earned $123.60 million during the quarter, compared to the consensus estimate of $119.71 million. Corcept Therapeutics had a trailing twelve-month return on equity of 18.99% and a net margin of 20.20%. The business's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the company posted $0.30 earnings per share. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC). What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (8.13%), Boston Trust Walden Corp (1.78%), Federated Hermes Inc. (1.64%), Northern Trust Corp (1.24%), Morgan Stanley (1.19%) and Invesco Ltd. (0.92%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CORT) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.